title: GLP-1 receptor agonists today.
abstract: Type 2 diabetes mellitus (T2DM) is a complex, progressive disease affecting an estimated 257 million people worldwide. A number of unmet needs exist with traditional T2DM therapies, which can lead to insufficient glycaemic control and increased risk of diabetes-associated complications. An emerging class of diabetes therapeutics, the glucagon-like peptide-1 (GLP-1) receptor agonists, appear to address many of the unmet needs of patients with T2DM. This review summarises the recent findings and current clinical guidelines of the currently approved GLP-1 receptor agonists and explores the new GLP-1 receptor agonists in development. It also concentrates on the physiological basis for early use of GLP-1 receptor agonists, their use as an alternative to insulin therapy, the rationale for combining them with insulin and their cost-effectiveness.
authors.affiliation: Department of Endocrinology, Diabetology and Nutrition, Bichat Hospital, Assistance Publique des Hôpitaux de Paris, 46 rue Henri Huchard, 75877 Paris Cedex 18, France. michel.marre@bch.aphp.fr
authors.forename: Michel
authors.initials: M
authors.lastname: Marre
authors.forename: Alfred
authors.initials: A
authors.lastname: Penfornis
mesh_terms: D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism*; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000627:therapeutic use; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000069450:Liraglutide; D010455:Peptides / Q000627:therapeutic use; D018027:Receptors, Glucagon / Q000819:agonists* / Q000378:metabolism; D014688:Venoms / Q000627:therapeutic use
chemical_list: C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D010455:Peptides; D018027:Receptors, Glucagon; D014688:Venoms; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide